Physician profile
Mark H Tabor
NPI 1467465153
$63,408.56
in general payments reported to CMS, 2019-2025
18 companies · $38K in 2025
The $38K reported for 2025 was more than what 99% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,675 · 2020: $6,854 · 2021: $3,566 · 2022: $1,194 · 2023: $2,749 · 2024: $8,691 · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $18K · Food and Beverage: $3,348 · Travel and Lodging: $3,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,612.00 |
| Consulting Fee | $18,073.00 |
| Food and Beverage | $3,348.11 |
| Travel and Lodging | $3,086.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21,828.89 | 2024-2025 | |
| Medtronic, INC. | $17,136.57 | 2022-2025 | Fusion, Propel, Nuvent |
| Medtronic USA, INC. | $7,425.98 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $7,059.17 | 2025 | Dupixent |
| Intersect Ent, INC. | $5,247.96 | 2020-2022 | |
| Regeneron Pharmaceuticals, INC. | $2,850.00 | 2024 | Dupixent |
| Depuy Synthes Sales INC. | $600.92 | 2022-2025 | Matrixmandible, Na |
| Stryker Corporation | $428.76 | 2025 | Scopis Ent, Nico Myriad Spectra, System 9 Cd Nxt |
| Aerin Medical INC. | $210.05 | 2019-2025 | |
| Acclarent, INC | $132.79 | 2019-2021 | |
| Integra Lifesciences Corporation | $126.74 | 2019 | |
| Baxter Healthcare | $94.11 | 2024 | Floseal |
| Mallinckrodt Hospital Products INC. | $94.11 | 2023 | Acthar |
| Allergan, INC. | $83.70 | 2019 | |
| Axogen | $40.97 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $22.19 | 2022 | |
| Optinose US, INC. | $14.04 | 2019 | |
| Pfizer INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tabor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.